Teladoc Health (NYSE:TDOC) PT Lowered to $16.00

Teladoc Health (NYSE:TDOC) had its target price reduced by equities researchers at JPMorgan Chase & Co. from $19.00 to $16.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “neutral” rating on the health services provider’s stock. JPMorgan Chase & Co.‘s price target would indicate a potential upside of 34.23% from the stock’s previous close.

Several other analysts have also weighed in on TDOC. Piper Sandler decreased their price target on Teladoc Health from $30.00 to $25.00 and set an “overweight” rating on the stock in a report on Wednesday, February 21st. Oppenheimer decreased their price target on Teladoc Health from $26.00 to $21.00 and set an “outperform” rating on the stock in a report on Friday, April 26th. Citigroup decreased their price target on Teladoc Health from $21.00 to $19.00 and set a “neutral” rating on the stock in a report on Wednesday, February 21st. Needham & Company LLC restated a “hold” rating on shares of Teladoc Health in a report on Friday, April 26th. Finally, Barclays decreased their price target on Teladoc Health from $25.00 to $20.00 and set an “overweight” rating on the stock in a report on Friday, April 26th. Thirteen research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, Teladoc Health presently has an average rating of “Hold” and a consensus price target of $18.22.

Teladoc Health Stock Up 0.8 %

NYSE TDOC opened at $11.92 on Tuesday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 3.74 and a current ratio of 3.82. The company has a market capitalization of $2.02 billion, a P/E ratio of -8.45 and a beta of 0.97. Teladoc Health has a one year low of $11.67 and a one year high of $30.41. The stock has a 50 day moving average price of $13.73 and a 200-day moving average price of $17.08.

Teladoc Health (NYSE:TDOC) last posted its earnings results on Thursday, April 25th. The health services provider reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.02). Teladoc Health had a negative net margin of 8.90% and a negative return on equity of 10.13%. The firm had revenue of $646.13 million for the quarter, compared to the consensus estimate of $637.31 million. During the same quarter in the prior year, the company posted ($0.37) earnings per share. The firm’s revenue was up 2.7% compared to the same quarter last year. As a group, equities analysts predict that Teladoc Health will post -1.04 EPS for the current fiscal year.

Insider Activity

In other news, insider Daniel Trencher sold 6,780 shares of the firm’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $14.52, for a total transaction of $98,445.60. Following the transaction, the insider now owns 28,192 shares in the company, valued at $409,347.84. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, insider Daniel Trencher sold 6,780 shares of the firm’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $14.52, for a total transaction of $98,445.60. Following the sale, the insider now owns 28,192 shares of the company’s stock, valued at $409,347.84. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Andrew Turitz sold 6,190 shares of the firm’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $14.52, for a total value of $89,878.80. Following the sale, the executive vice president now directly owns 39,429 shares in the company, valued at approximately $572,509.08. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 137,368 shares of company stock worth $1,968,587. Company insiders own 0.95% of the company’s stock.

Institutional Investors Weigh In On Teladoc Health

A number of institutional investors have recently added to or reduced their stakes in TDOC. Allspring Global Investments Holdings LLC boosted its holdings in Teladoc Health by 8.8% in the third quarter. Allspring Global Investments Holdings LLC now owns 50,903 shares of the health services provider’s stock worth $946,000 after acquiring an additional 4,129 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in Teladoc Health by 7.4% in the third quarter. Principal Financial Group Inc. now owns 12,774 shares of the health services provider’s stock worth $237,000 after acquiring an additional 883 shares in the last quarter. California Public Employees Retirement System boosted its holdings in Teladoc Health by 0.4% in the third quarter. California Public Employees Retirement System now owns 296,377 shares of the health services provider’s stock worth $5,510,000 after acquiring an additional 1,309 shares in the last quarter. Private Advisor Group LLC boosted its holdings in Teladoc Health by 110.5% in the third quarter. Private Advisor Group LLC now owns 58,253 shares of the health services provider’s stock worth $1,083,000 after acquiring an additional 30,583 shares in the last quarter. Finally, Victory Capital Management Inc. boosted its holdings in Teladoc Health by 4.3% in the third quarter. Victory Capital Management Inc. now owns 17,946 shares of the health services provider’s stock worth $334,000 after acquiring an additional 748 shares in the last quarter. Institutional investors own 76.82% of the company’s stock.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.